 |
|
Clopidogrel to Treat Patients With Non–ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge
Pierluigi Tricoci, MD;
Matthew T. Roe, MD, MHS;
Jyotsna Mulgund, MS;
L. Kristin Newby, MD, MHS;
Sidney C. Smith, Jr, MD;
Charles V. Pollack, Jr, MD, MA;
Dan J. Fintel, MD;
Christopher P. Cannon, MD;
Deepak L. Bhatt, MD;
W. Brian Gibler, MD;
E. Magnus Ohman, MD;
Eric D. Peterson, MD, MPH;
Robert A. Harrington, MD
Arch Intern Med. 2006;166:806-811.
Background Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non–ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach. The American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for treating NSTE ACS thus recommend prescribing clopidogrel plus aspirin at discharge for all patients, not just for those undergoing percutaneous coronary intervention (PCI).
Methods We studied 61 052 patients with high-risk NSTE ACS (defined as the presence of positive cardiac markers and/or ischemic ST-segment changes) from January 2002 through December 2003 at 461 US hospitals participating in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Quality Improvement Initiative. We evaluated temporal trends of clopidogrel use at discharge since the ACC/AHA 2002 Guidelines update and examined variables associated with clopidogrel use in patients who did not undergo PCI.
Results A total of 34 319 patients (56.2%) received clopidogrel when they were discharged from the hospital. Among patients who did not undergo PCI, variables associated with receiving clopidogrel at discharge included prior PCI, coronary artery bypass grafting (CABG), stroke, or myocardial infarction; hypercholesterolemia; elevated cardiac markers; and cardiology inpatient care. By late 2003, 96.3% of patients who underwent PCI received clopidogrel at discharge, compared with 42.8% of patients who did not undergo cardiac catheterization and 23.5% of the patients who underwent CABG, although clopidogrel prescription at discharge increased in each of these treatment groups from 2002 to 2003.
Conclusion Since release of the ACC/AHA Guidelines recommendations for treatment of NSTE ACS, prescription of clopidogrel at hospital discharge in patients with NSTE ACS who are treated with medical therapy alone and in those who undergo CABG has increased, but most of these patients still do not receive clopidogrel at discharge.
Author Affiliations: Division of Cardiology, Duke University School of Medicine, and Duke Clinical Research Institute, Durham, NC (Drs Tricoci, Roe, Newby, Peterson, and Harrington and Ms Mulgund); University of North Carolina School of Medicine, Chapel Hill (Drs Smith and Ohman); Pennsylvania Hospital, Philadelphia (Dr Pollack); Northwestern University School of Medicine, Chicago, Ill (Dr Fintel); TIMI Study Group, Brigham and Women's Hospital, Boston, Mass (Dr Cannon); Cleveland Clinic Foundation, Cleveland, Ohio (Dr Bhatt); and University of Cincinnati School of Medicine, Cincinnati, Ohio (Dr Gibler).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Clopidogrel in Patients With Acute Coronary Syndromes: Learning From Clinical Practice
Roy C. Ziegelstein
Arch Intern Med. 2006;166(20):2292-2293.
EXTRACT
| FULL TEXT
Clopidogrel in Patients With Acute Coronary Syndromes: Learning From Clinical Practice—Reply
Pierluigi Tricoci, Matthew T. Roe, and Eric D. Peterson
Arch Intern Med. 2006;166(20):2293.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine
Krumholz et al.
J Am Coll Cardiol 2008;52:2046-2099.
FULL TEXT
ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction): Developed in Collaboration With the American Academy of Family Physicians and the American College of Emergency Physicians: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine
WRITING COMMITTEE MEMBERS et al.
Circulation 2008;118:2596-2648.
FULL TEXT
Cardiovascular Outcomes after a Change in Prescription Policy for Clopidogrel
Jackevicius et al.
NEJM 2008;359:1802-1810.
ABSTRACT
| FULL TEXT
The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Douketis et al.
Chest 2008;133:299S-339S.
ABSTRACT
| FULL TEXT
Trends in Usage of Alternative Antiplatelet Therapy After Stroke and Transient Ischemic Attack
Hills and Johnston
Stroke 2008;39:1228-1232.
ABSTRACT
| FULL TEXT
Clopidogrel in Patients With Acute Coronary Syndromes: Learning From Clinical Practice--Reply
Tricoci et al.
Arch Intern Med 2006;166:2293-2293.
FULL TEXT
Clopidogrel in patients with acute coronary syndromes: learning from clinical practice.
Ziegelstein
Arch Intern Med 2006;166:2292-2293.
FULL TEXT
|
